

Special Issue

A New Era in the Treatment of Early-Stage Non-Small Cell Lung Cancer

Message from the Guest Editor

The standard of care for early-stage non-small cell lung cancer (NSCLC) has changed dramatically with increasing evidence for minimally invasive surgery, such as video-assisted thoracic surgery (VATS) and robotic-assisted thoracic surgery (RATS); sublobar resection, such as segmentectomy or wedge resection; and perioperative immunotherapy or targeted therapy. We are pleased to invite you to submit your experimental and theoretical results regarding new treatments for early-stage NSCLC. Full experimental details must be provided so that the results can be reproduced. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Minimally invasive surgery for lung cancer.
- Sublobar resection for early-stage NSCLC.
- Perioperative therapy for early-stage NSCLC.

I look forward to receiving your contributions.

Guest Editor

Prof. Dr. Tsutani Yasuhiro

Division of Thoracic Surgery, Department of Surgery, Kindai University
Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama 589-8511,
Japan

Deadline for manuscript submissions

31 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/194184

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)